If lower court rulings were left in place, they “would impose grave harms on the government, mifepristone’s sponsors, women seeking medication abortions, and the public,” Prelogar added. Among other things, access to the pill by mail — which the FDA formally approved in 2021 — would be curtailed.
Read more at NBC News